through a comprehensive literature review, the study found the effectiveness of covid-19 vaccines in people receiving arv treatments is similar to those without hiv.
“there is no evidence to support a lower immune response to covid-19 vaccines for people living with hiv and receiving antiretroviral treatment or people living with no hiv,” said yu.
this is good news for people living with hiv — the covid-19 vaccine will serve to protect them to the same degree as others.
people living with hiv who are undergoing arv treatments may benefit from their protective effects in the management of their response to the covid-19 virus.
those who are not receiving arv treatments or who have other health challenges may experience a more severe response to covid-19 infection. clinical and pharmacological management strategies need to be adapted to the unique treatment situations of each patient.
this is among the first research to examine the appropriate strategies to manage the effects of co-infection of covid-19 and hiv.
“we hope that our findings can help others better understand the pharmacological management of covid-19 and hiv co-infection and help co-infected patients achieve optimal therapy and a higher quality of life,” said yu.
the work is ongoing and is led by mr. chukwunonso nwabufo, a university of toronto doctoral student supervised by bendayan and who served as a day-to-day mentor for yu during the summer of 2021.
the team plans to draft a manuscript for submission to an academic journal in the near future.
“i have always enjoyed and loved the way research fed into my sense of curiosity and innovation. the unanswered questions and work that still needs to be done keeps driving me forward,” yu said.
the research was supported by the amgen foundation through the amgen scholars canada program. amgen scholars is an international program funded by the amgen foundation with technical and directional assistance provided by harvard university.